JP2019521167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521167A5 JP2019521167A5 JP2019502675A JP2019502675A JP2019521167A5 JP 2019521167 A5 JP2019521167 A5 JP 2019521167A5 JP 2019502675 A JP2019502675 A JP 2019502675A JP 2019502675 A JP2019502675 A JP 2019502675A JP 2019521167 A5 JP2019521167 A5 JP 2019521167A5
- Authority
- JP
- Japan
- Prior art keywords
- nicotinamide
- amino
- phenyl
- azabicyclo
- hexan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 152
- 229960003966 nicotinamide Drugs 0.000 claims 76
- 235000005152 nicotinamide Nutrition 0.000 claims 76
- 239000011570 nicotinamide Substances 0.000 claims 76
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 20
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- -1 optionally N Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 3
- JRWJZLHBSKAXJW-UHFFFAOYSA-N 2-amino-N-(4-hydroxy-4-methylcyclohexyl)-5-[4-[3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)(C)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C1CCOCC1 JRWJZLHBSKAXJW-UHFFFAOYSA-N 0.000 claims 2
- SRPLSQLPBCVKSL-UHFFFAOYSA-N 2-amino-N-cyclohexyl-5-[4-[2-(4-methylpiperazin-1-yl)ethylcarbamoyl]phenyl]pyridine-3-carboxamide Chemical compound CN1CCN(CCNC(=O)C2=CC=C(C=C2)C2=CN=C(N)C(=C2)C(=O)NC2CCCCC2)CC1 SRPLSQLPBCVKSL-UHFFFAOYSA-N 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 102100034111 Activin receptor type-1 Human genes 0.000 claims 2
- 206010049811 Extraskeletal ossification Diseases 0.000 claims 2
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 claims 2
- 208000034970 Heterotopic Ossification Diseases 0.000 claims 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- BAGWVDYVFGYURF-UHFFFAOYSA-N 2-amino-5-(2-fluoro-4-piperazin-1-ylphenyl)-N-(4-hydroxycyclohexyl)pyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C(=O)NC1CCC(O)CC1)C1=C(F)C=C(C=C1)N1CCNCC1 BAGWVDYVFGYURF-UHFFFAOYSA-N 0.000 claims 1
- MCKAROVXYQRNGJ-UHFFFAOYSA-N 2-amino-5-[2,3-difluoro-4-[(2-methylpyrrolidin-1-yl)methyl]phenyl]-N-(4-hydroxy-4-methylcyclohexyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)(C)O)C=C(C=N1)C1=C(C(=C(C=C1)CN1C(CCC1)C)F)F MCKAROVXYQRNGJ-UHFFFAOYSA-N 0.000 claims 1
- VPYFVDBWVBPVOQ-UHFFFAOYSA-N 2-amino-5-[2-chloro-4-[(2-methylpyrrolidin-1-yl)methyl]phenyl]-N-(4-hydroxy-4-methylcyclohexyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)(C)O)C=C(C=N1)C1=C(C=C(C=C1)CN1C(CCC1)C)Cl VPYFVDBWVBPVOQ-UHFFFAOYSA-N 0.000 claims 1
- IFZOMAMCUJXLIP-UHFFFAOYSA-N 2-amino-5-[2-chloro-4-[1-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethyl]phenyl]-N-(4-hydroxycyclohexyl)pyridine-3-carboxamide Chemical compound C1OCC11CN(C1)C(C)C1=CC(=C(C=C1)C=1C=NC(=C(C(=O)NC2CCC(CC2)O)C=1)N)Cl IFZOMAMCUJXLIP-UHFFFAOYSA-N 0.000 claims 1
- YPRRJKORYBKLRH-UHFFFAOYSA-N 2-amino-5-[2-fluoro-4-(4-propan-2-ylpiperazin-1-yl)phenyl]-N-(4-hydroxycyclohexyl)pyridine-3-carboxamide Chemical compound CC(C)N1CCN(CC1)C1=CC(F)=C(C=C1)C1=CN=C(N)C(=C1)C(=O)NC1CCC(O)CC1 YPRRJKORYBKLRH-UHFFFAOYSA-N 0.000 claims 1
- XASOXDFSRMCVGS-UHFFFAOYSA-N 2-amino-5-[2-fluoro-4-[(2-methylpyrrolidin-1-yl)methyl]phenyl]-N-(4-hydroxy-4-methylcyclohexyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)(C)O)C=C(C=N1)C1=C(C=C(C=C1)CN1C(CCC1)C)F XASOXDFSRMCVGS-UHFFFAOYSA-N 0.000 claims 1
- FBPYXJFVWDNZCF-UHFFFAOYSA-N 2-amino-5-[3-chloro-4-[(2-methylpyrrolidin-1-yl)methyl]phenyl]-N-(4-hydroxy-4-methylcyclohexyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)(C)O)C=C(C=N1)C1=CC(=C(C=C1)CN1C(CCC1)C)Cl FBPYXJFVWDNZCF-UHFFFAOYSA-N 0.000 claims 1
- VPAYUAUNRWCJTE-UHFFFAOYSA-N 2-amino-5-[4-(2-azaspiro[3.3]heptan-2-ylmethyl)phenyl]-N-(4-hydroxycyclohexyl)pyridine-3-carboxamide Chemical compound C1N(CC11CCC1)CC1=CC=C(C=C1)C=1C=NC(=C(C(=O)NC2CCC(CC2)O)C=1)N VPAYUAUNRWCJTE-UHFFFAOYSA-N 0.000 claims 1
- CCKKGJFQFLRASM-PDXDVJDWSA-N 2-amino-5-[4-[(1R,5S)-3-(2-fluoroethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CCC(CC2)(CC3)O)C=C(C=N1)C1=CC=C(C=C1)[C@@]12CN(C[C@H]2C1)CCF CCKKGJFQFLRASM-PDXDVJDWSA-N 0.000 claims 1
- RQXROVVCXFAAOM-OCVAFRRMSA-N 2-amino-5-[4-[(1R,5S)-3-(4,4-difluorocyclohexyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CCC(CC2)(CC3)O)C=C(C=N1)C1=CC=C(C=C1)[C@@]12CN(C[C@H]2C1)C1CCC(CC1)(F)F RQXROVVCXFAAOM-OCVAFRRMSA-N 0.000 claims 1
- CCKKGJFQFLRASM-VAMCUKFASA-N 2-amino-5-[4-[(1S,5R)-3-(2-fluoroethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)pyridine-3-carboxamide Chemical compound Nc1ncc(cc1C(=O)NC12CCC(O)(CC1)CC2)-c1ccc(cc1)[C@]12C[C@H]1CN(CCF)C2 CCKKGJFQFLRASM-VAMCUKFASA-N 0.000 claims 1
- RQXROVVCXFAAOM-GXLPGVSKSA-N 2-amino-5-[4-[(1S,5R)-3-(4,4-difluorocyclohexyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)pyridine-3-carboxamide Chemical compound Nc1ncc(cc1C(=O)NC12CCC(O)(CC1)CC2)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCC(F)(F)CC1 RQXROVVCXFAAOM-GXLPGVSKSA-N 0.000 claims 1
- ZNGBDCDUILRYET-UHFFFAOYSA-N 2-amino-5-[4-[3-(1,3-difluoropropan-2-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxycyclohexyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C(CF)CF ZNGBDCDUILRYET-UHFFFAOYSA-N 0.000 claims 1
- PBPRYPLWJIJEMD-UHFFFAOYSA-N 2-amino-5-[4-[3-(2,2-difluoropropyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxycyclohexyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)CC(C)(F)F PBPRYPLWJIJEMD-UHFFFAOYSA-N 0.000 claims 1
- JXPPULPLYFLFJI-UHFFFAOYSA-N 2-amino-5-[4-[3-(2-cyanoethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxycyclohexyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)CCC#N JXPPULPLYFLFJI-UHFFFAOYSA-N 0.000 claims 1
- CCKKGJFQFLRASM-UHFFFAOYSA-N 2-amino-5-[4-[3-(2-fluoroethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CCC(CC2)(CC3)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)CCF CCKKGJFQFLRASM-UHFFFAOYSA-N 0.000 claims 1
- MOTRKLJWPDOTBN-UHFFFAOYSA-N 2-amino-5-[4-[3-(2-fluoroethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxycyclohexyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)CCF MOTRKLJWPDOTBN-UHFFFAOYSA-N 0.000 claims 1
- RQXROVVCXFAAOM-UHFFFAOYSA-N 2-amino-5-[4-[3-(4,4-difluorocyclohexyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CCC(CC2)(CC3)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C1CCC(CC1)(F)F RQXROVVCXFAAOM-UHFFFAOYSA-N 0.000 claims 1
- NZDLTZYLNOKWBF-UHFFFAOYSA-N 2-amino-5-[4-[3-(4,4-difluorocyclohexyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxy-4-methylcyclohexyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)(C)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C1CCC(CC1)(F)F NZDLTZYLNOKWBF-UHFFFAOYSA-N 0.000 claims 1
- WCTODNJGIAJWJX-UHFFFAOYSA-N 2-amino-5-[4-[3-(4,4-difluorocyclohexyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]-N-(4-hydroxycyclohexyl)pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C1CCC(CC1)(F)F WCTODNJGIAJWJX-UHFFFAOYSA-N 0.000 claims 1
- ODVUZZFWFOPOAH-UHFFFAOYSA-N 2-amino-N-(3-fluoro-4-hydroxycyclohexyl)-5-[4-[3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CC(C(CC2)O)F)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C1CCOCC1 ODVUZZFWFOPOAH-UHFFFAOYSA-N 0.000 claims 1
- QYYWOEFGZQFXCP-UHFFFAOYSA-N 2-amino-N-(3-hydroxy-1-adamantyl)-5-[4-[1-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethyl]phenyl]pyridine-3-carboxamide Chemical compound C1OCC11CN(C1)C(C)C1=CC=C(C=C1)C=1C=NC(=C(C(=O)NC23CC4(CC(CC(C2)C4)C3)O)C=1)N QYYWOEFGZQFXCP-UHFFFAOYSA-N 0.000 claims 1
- HZFKGEGMOFIQKL-JDANMYFYSA-N 2-amino-N-(4-deuterio-4-hydroxycyclohexyl)-5-[4-(3-propan-2-yl-3-azabicyclo[3.1.0]hexan-1-yl)phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)([2H])O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C(C)C HZFKGEGMOFIQKL-JDANMYFYSA-N 0.000 claims 1
- GAIBPGQSYNAFNN-XSVJXTIASA-N 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[(1R,5S)-3-(2-morpholin-4-ylethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CCC(CC2)(CC3)O)C=C(C=N1)C1=CC=C(C=C1)[C@@]12CN(C[C@H]2C1)CCN1CCOCC1 GAIBPGQSYNAFNN-XSVJXTIASA-N 0.000 claims 1
- GHUBYLSYFHNRLX-BORAJFNMSA-N 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CCC(CC2)(CC3)O)C=C(C=N1)C1=CC=C(C=C1)[C@@]12CN(C[C@H]2C1)C1COC1 GHUBYLSYFHNRLX-BORAJFNMSA-N 0.000 claims 1
- GNDTWZQOAXPKCV-DTHGUCGZSA-N 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[(1S,5R)-3-(2-methoxyethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound COCCN1C[C@@H]2C[C@@]2(C1)c1ccc(cc1)-c1cnc(N)c(c1)C(=O)NC12CCC(O)(CC1)CC2 GNDTWZQOAXPKCV-DTHGUCGZSA-N 0.000 claims 1
- GAIBPGQSYNAFNN-BVPJRLQBSA-N 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[(1S,5R)-3-(2-morpholin-4-ylethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound Nc1ncc(cc1C(=O)NC12CCC(O)(CC1)CC2)-c1ccc(cc1)[C@]12C[C@H]1CN(CCN1CCOCC1)C2 GAIBPGQSYNAFNN-BVPJRLQBSA-N 0.000 claims 1
- GHUBYLSYFHNRLX-ZKSXBLTCSA-N 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[(1S,5R)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound Nc1ncc(cc1C(=O)NC12CCC(O)(CC1)CC2)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1COC1 GHUBYLSYFHNRLX-ZKSXBLTCSA-N 0.000 claims 1
- GNDTWZQOAXPKCV-UHFFFAOYSA-N 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[3-(2-methoxyethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CCC(CC2)(CC3)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)CCOC GNDTWZQOAXPKCV-UHFFFAOYSA-N 0.000 claims 1
- GAIBPGQSYNAFNN-UHFFFAOYSA-N 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[3-(2-morpholin-4-ylethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CCC(CC2)(CC3)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)CCN1CCOCC1 GAIBPGQSYNAFNN-UHFFFAOYSA-N 0.000 claims 1
- KPRPFTOLWQQUAV-UHFFFAOYSA-N 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CCC(CC2)(CC3)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C1CCOCC1 KPRPFTOLWQQUAV-UHFFFAOYSA-N 0.000 claims 1
- VYIZLEBMEIYFLA-UHFFFAOYSA-N 2-amino-N-(4-hydroxy-1-methylcyclohexyl)-5-[4-[1-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethyl]phenyl]pyridine-3-carboxamide Chemical compound C1OCC11CN(C1)C(C)C1=CC=C(C=C1)C=1C=NC(=C(C(=O)NC2(CCC(CC2)O)C)C=1)N VYIZLEBMEIYFLA-UHFFFAOYSA-N 0.000 claims 1
- DYPKOAOCIPJRSB-UHFFFAOYSA-N 2-amino-N-(4-hydroxy-4-methylcyclohexyl)-5-[2-methyl-4-[(2-methylpyrrolidin-1-yl)methyl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)(C)O)C=C(C=N1)C1=C(C=C(C=C1)CN1C(CCC1)C)C DYPKOAOCIPJRSB-UHFFFAOYSA-N 0.000 claims 1
- DBAUTMSTTOYZCH-UHFFFAOYSA-N 2-amino-N-(4-hydroxy-4-methylcyclohexyl)-5-[4-(3-propan-2-yl-3-azabicyclo[3.1.0]hexan-1-yl)phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)(C)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C(C)C DBAUTMSTTOYZCH-UHFFFAOYSA-N 0.000 claims 1
- JAGKUGSFENQDHG-UHFFFAOYSA-N 2-amino-N-(4-hydroxy-4-methylcyclohexyl)-5-[4-[(2-methylpyrrolidin-1-yl)methyl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)(C)O)C=C(C=N1)C1=CC=C(C=C1)CN1C(CCC1)C JAGKUGSFENQDHG-UHFFFAOYSA-N 0.000 claims 1
- XBGQOGKKOFCYQD-UHFFFAOYSA-N 2-amino-N-(4-hydroxy-4-methylcyclohexyl)-5-[4-[1-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethyl]phenyl]pyridine-3-carboxamide Chemical compound C1OCC11CN(C1)C(C)C1=CC=C(C=C1)C=1C=NC(=C(C(=O)NC2CCC(CC2)(C)O)C=1)N XBGQOGKKOFCYQD-UHFFFAOYSA-N 0.000 claims 1
- AKSKEXPIRSTUBP-UHFFFAOYSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-(4-pyrrolidin-3-ylphenyl)pyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C(=O)NC1CCC(O)CC1)C1=CC=C(C=C1)C1CCNC1 AKSKEXPIRSTUBP-UHFFFAOYSA-N 0.000 claims 1
- ZYBANBICDUFKMJ-UHFFFAOYSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-[4-(1-propan-2-ylpyrrolidin-3-yl)phenyl]pyridine-3-carboxamide Chemical compound CC(C)N1CCC(C1)C1=CC=C(C=C1)C1=CN=C(N)C(=C1)C(=O)NC1CCC(O)CC1 ZYBANBICDUFKMJ-UHFFFAOYSA-N 0.000 claims 1
- HZFKGEGMOFIQKL-UHFFFAOYSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-[4-(3-propan-2-yl-3-azabicyclo[3.1.0]hexan-1-yl)phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C(C)C HZFKGEGMOFIQKL-UHFFFAOYSA-N 0.000 claims 1
- ZWIZYDKWXQTSEQ-UHFFFAOYSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridine-3-carboxamide Chemical compound CN1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CN=C(N)C(=C1)C(=O)NC1CCC(O)CC1 ZWIZYDKWXQTSEQ-UHFFFAOYSA-N 0.000 claims 1
- WTEJOBNHOMFLQN-UHFFFAOYSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-[4-[(2-methylpyrrolidin-1-yl)methyl]phenyl]pyridine-3-carboxamide Chemical compound CC1CCCN1Cc1ccc(cc1)-c1cnc(N)c(c1)C(=O)NC1CCC(O)CC1 WTEJOBNHOMFLQN-UHFFFAOYSA-N 0.000 claims 1
- GPLMXGSESNBQQL-UHFFFAOYSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-[4-[1-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethyl]phenyl]pyridine-3-carboxamide Chemical compound C1OCC11CN(C1)C(C)C1=CC=C(C=C1)C=1C=NC(=C(C(=O)NC2CCC(CC2)O)C=1)N GPLMXGSESNBQQL-UHFFFAOYSA-N 0.000 claims 1
- NJSRQYMTTJJEJH-UHFFFAOYSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-[4-[3-(2-methoxyethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)CCOC NJSRQYMTTJJEJH-UHFFFAOYSA-N 0.000 claims 1
- JFDSOYMKCLUKEJ-UHFFFAOYSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-[4-[3-(2-morpholin-4-ylethyl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)CCN1CCOCC1 JFDSOYMKCLUKEJ-UHFFFAOYSA-N 0.000 claims 1
- RCORIFCNLQIMKN-UHFFFAOYSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-[4-[3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C1COC1 RCORIFCNLQIMKN-UHFFFAOYSA-N 0.000 claims 1
- IOEZZOIIFUBFFP-UHFFFAOYSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-[4-[3-[2-(2,2,2-trifluoroethoxy)ethyl]-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC2CCC(CC2)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)CCOCC(F)(F)F IOEZZOIIFUBFFP-UHFFFAOYSA-N 0.000 claims 1
- WTEJOBNHOMFLQN-YMTQGWHGSA-N 2-amino-N-(4-hydroxycyclohexyl)-5-[4-[[(2R)-2-methylpyrrolidin-1-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound C[C@@H]1CCCN1CC1=CC=C(C=C1)C1=CN=C(N)C(=C1)C(=O)NC1CCC(O)CC1 WTEJOBNHOMFLQN-YMTQGWHGSA-N 0.000 claims 1
- UJOAYZNRVRGXPF-SAQMYGGWSA-N 2-amino-N-[3-(2-hydroxypropan-2-yl)-1-bicyclo[1.1.1]pentanyl]-5-[4-[(1R,5S)-3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CC(C2)(C3)C(C)(C)O)C=C(C=N1)C1=CC=C(C=C1)[C@@]12CN(C[C@H]2C1)C1CCOCC1 UJOAYZNRVRGXPF-SAQMYGGWSA-N 0.000 claims 1
- UJOAYZNRVRGXPF-UHFFFAOYSA-N 2-amino-N-[3-(2-hydroxypropan-2-yl)-1-bicyclo[1.1.1]pentanyl]-5-[4-[3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CC(C2)(C3)C(C)(C)O)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C1CCOCC1 UJOAYZNRVRGXPF-UHFFFAOYSA-N 0.000 claims 1
- WBRIXUZLHYMBMA-UHFFFAOYSA-N 2-amino-N-[3-(hydroxymethyl)-1-bicyclo[1.1.1]pentanyl]-5-[4-(3-propan-2-yl-3-azabicyclo[3.1.0]hexan-1-yl)phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CC(C2)(C3)CO)C=C(C=N1)C1=CC=C(C=C1)C12CN(CC2C1)C(C)C WBRIXUZLHYMBMA-UHFFFAOYSA-N 0.000 claims 1
- MEDZXCCPJFWNLJ-BORAJFNMSA-N 2-amino-N-[3-(hydroxymethyl)-1-bicyclo[1.1.1]pentanyl]-5-[4-[(1R,5S)-3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CC(C2)(C3)CO)C=C(C=N1)C1=CC=C(C=C1)[C@@]12CN(C[C@H]2C1)C1CCOCC1 MEDZXCCPJFWNLJ-BORAJFNMSA-N 0.000 claims 1
- WBRIXUZLHYMBMA-QQYNMQCVSA-N 2-amino-N-[3-(hydroxymethyl)-1-bicyclo[1.1.1]pentanyl]-5-[4-[(1R,5S)-3-propan-2-yl-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CC(C2)(C3)CO)C=C(C=N1)C1=CC=C(C=C1)[C@@]12CN(C[C@H]2C1)C(C)C WBRIXUZLHYMBMA-QQYNMQCVSA-N 0.000 claims 1
- MEDZXCCPJFWNLJ-ZKSXBLTCSA-N 2-amino-N-[3-(hydroxymethyl)-1-bicyclo[1.1.1]pentanyl]-5-[4-[(1S,5R)-3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CC(C2)(C3)CO)C=C(C=N1)C1=CC=C(C=C1)[C@]12CN(C[C@@H]2C1)C1CCOCC1 MEDZXCCPJFWNLJ-ZKSXBLTCSA-N 0.000 claims 1
- WBRIXUZLHYMBMA-PMISWQISSA-N 2-amino-N-[3-(hydroxymethyl)-1-bicyclo[1.1.1]pentanyl]-5-[4-[(1S,5R)-3-propan-2-yl-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CC(C2)(C3)CO)C=C(C=N1)C1=CC=C(C=C1)[C@]12CN(C[C@@H]2C1)C(C)C WBRIXUZLHYMBMA-PMISWQISSA-N 0.000 claims 1
- LDFGETAUTXIODG-UHFFFAOYSA-N 2-amino-N-cyclohexyl-5-(4-morpholin-4-ylphenyl)pyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C(=O)NC1CCCCC1)C1=CC=C(C=C1)N1CCOCC1 LDFGETAUTXIODG-UHFFFAOYSA-N 0.000 claims 1
- RVRSJCNFHLBUKI-UHFFFAOYSA-N 2-amino-N-cyclohexyl-5-(4-piperidin-1-ylphenyl)pyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C(=O)NC1CCCCC1)C1=CC=C(C=C1)N1CCCCC1 RVRSJCNFHLBUKI-UHFFFAOYSA-N 0.000 claims 1
- LJYGDHOBWBXZIU-UHFFFAOYSA-N 2-amino-N-cyclohexyl-5-[3-(morpholine-4-carbonyl)phenyl]pyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C(=O)NC1CCCCC1)C1=CC(=CC=C1)C(=O)N1CCOCC1 LJYGDHOBWBXZIU-UHFFFAOYSA-N 0.000 claims 1
- KPONRYYSJPIILR-UHFFFAOYSA-N 2-amino-N-cyclohexyl-5-[4-(3-morpholin-4-ylpropoxy)phenyl]pyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C(=O)NC1CCCCC1)C1=CC=C(OCCCN2CCOCC2)C=C1 KPONRYYSJPIILR-UHFFFAOYSA-N 0.000 claims 1
- FJHJLNXCFAIWOY-UHFFFAOYSA-N 2-amino-N-cyclohexyl-5-[4-(3-piperidin-1-ylpropoxy)phenyl]pyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C(=O)NC1CCCCC1)C1=CC=C(OCCCN2CCCCC2)C=C1 FJHJLNXCFAIWOY-UHFFFAOYSA-N 0.000 claims 1
- ZROZDTQXWWJRDP-UHFFFAOYSA-N 2-amino-N-cyclohexyl-5-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridine-3-carboxamide Chemical compound CN1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CN=C(N)C(=C1)C(=O)NC1CCCCC1 ZROZDTQXWWJRDP-UHFFFAOYSA-N 0.000 claims 1
- QLKTYOQNNHTKLX-UHFFFAOYSA-N 2-amino-N-cyclohexyl-5-[4-(morpholine-4-carbonyl)phenyl]pyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C(=O)NC1CCCCC1)C1=CC=C(C=C1)C(=O)N1CCOCC1 QLKTYOQNNHTKLX-UHFFFAOYSA-N 0.000 claims 1
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022025894A JP7253086B2 (ja) | 2016-07-20 | 2022-02-22 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2023048083A JP7584553B2 (ja) | 2016-07-20 | 2023-03-24 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2024193634A JP7834830B2 (ja) | 2016-07-20 | 2024-11-05 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364620P | 2016-07-20 | 2016-07-20 | |
| US62/364,620 | 2016-07-20 | ||
| PCT/CN2017/093385 WO2018014829A1 (en) | 2016-07-20 | 2017-07-18 | Aminopyridine derivatives and their use as selective alk-2 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025894A Division JP7253086B2 (ja) | 2016-07-20 | 2022-02-22 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521167A JP2019521167A (ja) | 2019-07-25 |
| JP2019521167A5 true JP2019521167A5 (enExample) | 2020-08-27 |
| JP7030776B2 JP7030776B2 (ja) | 2022-03-07 |
Family
ID=60991950
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502675A Active JP7030776B2 (ja) | 2016-07-20 | 2017-07-18 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2022025894A Active JP7253086B2 (ja) | 2016-07-20 | 2022-02-22 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2023048083A Active JP7584553B2 (ja) | 2016-07-20 | 2023-03-24 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2024193634A Active JP7834830B2 (ja) | 2016-07-20 | 2024-11-05 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025894A Active JP7253086B2 (ja) | 2016-07-20 | 2022-02-22 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2023048083A Active JP7584553B2 (ja) | 2016-07-20 | 2023-03-24 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2024193634A Active JP7834830B2 (ja) | 2016-07-20 | 2024-11-05 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10710980B2 (enExample) |
| EP (3) | EP3971177B1 (enExample) |
| JP (4) | JP7030776B2 (enExample) |
| KR (7) | KR102281550B1 (enExample) |
| CN (2) | CN114014844B (enExample) |
| AR (1) | AR109108A1 (enExample) |
| AU (5) | AU2017298187B2 (enExample) |
| CY (1) | CY1124967T1 (enExample) |
| DK (2) | DK3971177T3 (enExample) |
| EA (2) | EA037520B1 (enExample) |
| ES (2) | ES2902521T3 (enExample) |
| FI (1) | FI3971177T3 (enExample) |
| HR (2) | HRP20241015T1 (enExample) |
| HU (2) | HUE067992T2 (enExample) |
| LT (2) | LT3971177T (enExample) |
| MX (2) | MX388518B (enExample) |
| PL (2) | PL3487851T3 (enExample) |
| PT (2) | PT3487851T (enExample) |
| RS (2) | RS62819B1 (enExample) |
| RU (1) | RU2747318C2 (enExample) |
| SI (2) | SI3487851T1 (enExample) |
| SM (2) | SMT202100723T1 (enExample) |
| TW (4) | TWI851226B (enExample) |
| UY (1) | UY37331A (enExample) |
| WO (1) | WO2018014829A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7030776B2 (ja) | 2016-07-20 | 2022-03-07 | ノバルティス アーゲー | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| BR112022009710A2 (pt) * | 2019-11-22 | 2022-08-09 | Incyte Corp | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 |
| CN111170893B (zh) * | 2020-01-19 | 2022-04-26 | 郑州依米花手性药物研究有限公司 | Lefamulin的中间体化合物及其在Lefamulin制备中的应用 |
| CA3187767A1 (en) * | 2020-06-16 | 2021-12-23 | Incyte Corporation | Alk2 inhibitors for the treatment of anemia |
| KR102913358B1 (ko) * | 2020-10-29 | 2026-01-14 | 주식회사 엘지화학 | 중수소화 화합물의 분석방법, 소자 제조용 중수소화 화합물의 선별방법 및 전자 소자의 제조방법 |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| CN116478145B (zh) * | 2022-04-13 | 2024-02-02 | 杭州邦顺制药有限公司 | Alk2激酶抑制剂 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077290A (en) | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| WO1994011502A2 (en) | 1992-11-17 | 1994-05-26 | Ludwig Institute For Cancer Research | Activin receptor-like kinases, proteins having serine threonine kinase domains and their use |
| TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| US6914058B2 (en) | 2002-01-18 | 2005-07-05 | Dr. Reddy's Laboratories, Limited | Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them |
| CA2484209C (en) | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7015227B2 (en) | 2002-06-21 | 2006-03-21 | Cgi Pharmaceuticals, Inc. | Certain amino-substituted monocycles as kinase modulators |
| US20040067985A1 (en) | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| SE0203753D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2004230519A1 (en) | 2003-04-11 | 2004-10-28 | Sgx Pharmaceuticals, Inc. | Compound libraries and methods for drug discovery |
| MXPA06013786A (es) | 2004-05-27 | 2007-01-25 | Pfizer | Nuevos derivados de aminopiridina y su uso como farmacos. |
| SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| JPWO2006109876A1 (ja) | 2005-04-08 | 2008-11-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 不随意運動治療剤 |
| WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| GB0517175D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| PE20071240A1 (es) | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
| US8895711B2 (en) | 2006-04-18 | 2014-11-25 | The Trustees Of The University Of Pennsylvania | Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP) |
| US20080021024A1 (en) | 2006-06-29 | 2008-01-24 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| KR20090088852A (ko) | 2006-09-05 | 2009-08-20 | 메다렉스, 인코포레이티드 | 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법 |
| EP2062048A4 (en) | 2006-09-12 | 2009-12-02 | Gen Hospital Corp | METHOD FOR IDENTIFYING CELL SIGNALING MODULATING COMPOUNDS AND METHOD FOR USING SUCH COMPOSITES |
| UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| CN102203074A (zh) | 2008-06-20 | 2011-09-28 | 麦它波莱克斯股份有限公司 | 芳基gpr119激动剂及其用途 |
| WO2012023113A2 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Designer osteogenic proteins |
| KR20140014104A (ko) | 2010-12-06 | 2014-02-05 | 피라말 엔터프라이지즈 리미티드 | 치환된 이미다조퀴놀린 유도체 |
| WO2012087938A1 (en) | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Quinazolinone derivatives as antiviral agents |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| CA2832605C (en) | 2011-05-23 | 2016-03-29 | Merck Patent Gmbh | Pyridine-and pyrazine derivatives |
| US9550000B2 (en) | 2011-09-09 | 2017-01-24 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| EP2900238B1 (en) | 2012-09-28 | 2017-12-06 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| US20160115167A1 (en) * | 2013-03-04 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| JP6433974B2 (ja) * | 2013-03-14 | 2018-12-05 | トレロ ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法 |
| US9682983B2 (en) | 2013-03-14 | 2017-06-20 | The Brigham And Women's Hospital, Inc. | BMP inhibitors and methods of use thereof |
| KR20160063366A (ko) | 2013-10-21 | 2016-06-03 | 메르크 파텐트 게엠베하 | Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도 |
| US10260068B2 (en) | 2014-03-31 | 2019-04-16 | Sumitomo Dainippon Pharma Co., Ltd. | Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva |
| EP3247701B1 (en) | 2015-01-20 | 2021-09-22 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic compounds, compositions and method of using thereof |
| BR112018004065B1 (pt) | 2015-08-31 | 2023-12-12 | Dong-A Socio Holdings Co., Ltd | Compostos heterocíclicos, composições farmacêuticas compreendendo os ditos compostos e usos terapêuticos dos mesmos |
| US11462835B2 (en) | 2016-07-20 | 2022-10-04 | Qorvo Us, Inc. | Method for tuning an antenna with a DVC |
| JP7030776B2 (ja) * | 2016-07-20 | 2022-03-07 | ノバルティス アーゲー | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
-
2017
- 2017-07-18 JP JP2019502675A patent/JP7030776B2/ja active Active
- 2017-07-18 MX MX2019000837A patent/MX388518B/es unknown
- 2017-07-18 TW TW112118991A patent/TWI851226B/zh active
- 2017-07-18 TW TW111103316A patent/TWI806385B/zh active
- 2017-07-18 DK DK21202619.9T patent/DK3971177T3/da active
- 2017-07-18 CN CN202111145806.6A patent/CN114014844B/zh active Active
- 2017-07-18 SM SM20210723T patent/SMT202100723T1/it unknown
- 2017-07-18 KR KR1020197004529A patent/KR102281550B1/ko active Active
- 2017-07-18 KR KR1020227034980A patent/KR102559539B1/ko active Active
- 2017-07-18 KR KR1020227003660A patent/KR102454129B1/ko active Active
- 2017-07-18 EP EP21202619.9A patent/EP3971177B1/en active Active
- 2017-07-18 LT LTEP21202619.9T patent/LT3971177T/lt unknown
- 2017-07-18 HU HUE21202619A patent/HUE067992T2/hu unknown
- 2017-07-18 PT PT178304630T patent/PT3487851T/pt unknown
- 2017-07-18 KR KR1020217022916A patent/KR102359707B1/ko active Active
- 2017-07-18 EA EA201990343A patent/EA037520B1/ru unknown
- 2017-07-18 AU AU2017298187A patent/AU2017298187B2/en active Active
- 2017-07-18 FI FIEP21202619.9T patent/FI3971177T3/fi active
- 2017-07-18 KR KR1020237024969A patent/KR102667331B1/ko active Active
- 2017-07-18 HU HUE17830463A patent/HUE057328T2/hu unknown
- 2017-07-18 HR HRP20241015TT patent/HRP20241015T1/hr unknown
- 2017-07-18 PL PL17830463T patent/PL3487851T3/pl unknown
- 2017-07-18 EP EP17830463.0A patent/EP3487851B1/en active Active
- 2017-07-18 DK DK17830463.0T patent/DK3487851T3/da active
- 2017-07-18 HR HRP20211868TT patent/HRP20211868T1/hr unknown
- 2017-07-18 SI SI201731040T patent/SI3487851T1/sl unknown
- 2017-07-18 RU RU2019104609A patent/RU2747318C2/ru active
- 2017-07-18 EP EP24183394.6A patent/EP4442317A3/en active Pending
- 2017-07-18 US US16/318,250 patent/US10710980B2/en active Active
- 2017-07-18 PT PT212026199T patent/PT3971177T/pt unknown
- 2017-07-18 TW TW106123900A patent/TWI712598B/zh active
- 2017-07-18 KR KR1020247016068A patent/KR102719881B1/ko active Active
- 2017-07-18 LT LTEPPCT/CN2017/093385T patent/LT3487851T/lt unknown
- 2017-07-18 WO PCT/CN2017/093385 patent/WO2018014829A1/en not_active Ceased
- 2017-07-18 RS RS20211582A patent/RS62819B1/sr unknown
- 2017-07-18 CN CN201780044640.4A patent/CN109641871B/zh active Active
- 2017-07-18 SI SI201731538T patent/SI3971177T1/sl unknown
- 2017-07-18 PL PL21202619.9T patent/PL3971177T3/pl unknown
- 2017-07-18 EA EA202190285A patent/EA202190285A1/ru unknown
- 2017-07-18 RS RS20241041A patent/RS66041B1/sr unknown
- 2017-07-18 SM SM20240335T patent/SMT202400335T1/it unknown
- 2017-07-18 KR KR1020247034434A patent/KR20240155367A/ko active Pending
- 2017-07-18 ES ES17830463T patent/ES2902521T3/es active Active
- 2017-07-18 TW TW110101592A patent/TWI755255B/zh active
- 2017-07-18 ES ES21202619T patent/ES2984746T3/es active Active
- 2017-07-19 UY UY0001037331A patent/UY37331A/es not_active Application Discontinuation
- 2017-07-20 AR ARP170102033A patent/AR109108A1/es active IP Right Grant
-
2019
- 2019-01-18 MX MX2021014852A patent/MX2021014852A/es unknown
- 2019-10-10 AU AU2019246857A patent/AU2019246857B2/en active Active
-
2020
- 2020-05-27 US US16/884,666 patent/US10947218B2/en active Active
-
2021
- 2021-02-08 US US17/170,690 patent/US12466808B2/en active Active
- 2021-03-04 AU AU2021201424A patent/AU2021201424C1/en active Active
- 2021-12-29 CY CY20211101137T patent/CY1124967T1/el unknown
-
2022
- 2022-02-22 JP JP2022025894A patent/JP7253086B2/ja active Active
-
2023
- 2023-01-19 AU AU2023200265A patent/AU2023200265B2/en active Active
- 2023-03-24 JP JP2023048083A patent/JP7584553B2/ja active Active
-
2024
- 2024-07-24 AU AU2024205058A patent/AU2024205058A1/en active Pending
- 2024-11-05 JP JP2024193634A patent/JP7834830B2/ja active Active
-
2025
- 2025-10-01 US US19/347,428 patent/US20260116869A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6218260B2 (ja) | Ｊａｋ阻害剤としてのアミノピリミジニル化合物 | |
| RU2019104609A (ru) | Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2 | |
| AU2014291711B2 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| AU2014364744B2 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| JP2010508338A5 (enExample) | ||
| RU2011107437A (ru) | Ингибиторы кинуренин-3-моноксигеназы | |
| US10023576B2 (en) | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | |
| EP3209664B1 (en) | Bicyclic heteroaryl amine compounds as pi3k inhibitors | |
| RU2017135520A (ru) | Бициклические производные хиназолинона | |
| RU2016144202A (ru) | АНАЛОГИ СОЕДИНЕНИЙ 4Н-ПИРАЗОЛО[1,5-a]БЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ PARP | |
| CN101605540A (zh) | 使用mek抑制剂的方法 | |
| BR112016010041A2 (pt) | composto, medicamento, e, uso do composto ou sal | |
| WO2019224773A1 (en) | Heterocyclic amides as rip1 kinase inhibitors | |
| AU2021242143B2 (en) | Aminopyrimidine derivatives and their use as Aryl hydrocarbon receptor modulators | |
| BR112019010164A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar aterosclerose, esteatose hepática, aterosclerose, diabetes mellitus tipo 2, obesidade, hiperlipidemia ou hipercolesterolemia. | |
| JP2018522929A5 (enExample) | ||
| US20160175316A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| JP2018515489A5 (enExample) | ||
| JP2018505145A5 (enExample) | ||
| CA3246382A1 (en) | SMALL MOLECULES INHIBITING MEMBERS OF THE TEAD FAMILY (TEA DOMAIN) | |
| WO2019197269A1 (en) | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer | |
| JP2025505609A5 (enExample) | ||
| RU2024125208A (ru) | Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2 | |
| US20210369724A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |